CorMedix IncNASDAQ:CRMD
- LAST PRICE7.5700
- TODAY'S CHANGE (%)0.0600 (0.7989%)
- Bid / Lots7.5600/ 3
- Ask / Lots7.5800/ 4
- Open / Previous Close7.5200 / 7.5100
- Day Range
- 52 Week Range
- Volume599,763
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRMD |
|---|---|---|
| 09:32 ET | 14155 | 7.44 |
| 09:34 ET | 5201 | 7.37 |
| 09:36 ET | 17591 | 7.415 |
| 09:38 ET | 5663 | 7.42 |
| 09:39 ET | 100 | 7.4 |
| 09:41 ET | 2800 | 7.4 |
| 09:43 ET | 100 | 7.42 |
| 09:45 ET | 1598 | 7.4 |
| 09:48 ET | 18041 | 7.475 |
| 09:50 ET | 5942 | 7.495 |
| 09:52 ET | 3481 | 7.5 |
| 09:54 ET | 4683 | 7.52 |
| 09:56 ET | 4100 | 7.5 |
| 09:57 ET | 1821 | 7.5 |
| 09:59 ET | 15800 | 7.56 |
| 10:01 ET | 200 | 7.58 |
| 10:03 ET | 32995 | 7.6 |
| 10:06 ET | 26419 | 7.58 |
| 10:08 ET | 20935 | 7.585 |
| 10:10 ET | 6540 | 7.5701 |
| 10:12 ET | 72995 | 7.6 |
| 10:14 ET | 12224 | 7.58 |
| 10:15 ET | 39425 | 7.6 |
| 10:17 ET | 1700 | 7.645 |
| 10:19 ET | 27800 | 7.64 |
| 10:21 ET | 8500 | 7.59 |
| 10:24 ET | 3942 | 7.58 |
| 10:26 ET | 3451 | 7.6 |
| 10:28 ET | 10108 | 7.61 |
| 10:30 ET | 722 | 7.61 |
| 10:32 ET | 2377 | 7.6097 |
| 10:33 ET | 7545 | 7.6394 |
| 10:35 ET | 2691 | 7.64 |
| 10:37 ET | 9471 | 7.605 |
| 10:39 ET | 4816 | 7.615 |
| 10:42 ET | 950 | 7.62 |
| 10:44 ET | 1200 | 7.62 |
| 10:46 ET | 1900 | 7.62 |
| 10:48 ET | 2550 | 7.6184 |
| 10:50 ET | 4421 | 7.58 |
| 10:51 ET | 13343 | 7.6 |
| 10:53 ET | 1974 | 7.55 |
| 10:55 ET | 1400 | 7.542 |
| 10:57 ET | 2736 | 7.5659 |
| 11:00 ET | 800 | 7.56 |
| 11:02 ET | 1051 | 7.57 |
| 11:04 ET | 12553 | 7.57 |
| 11:06 ET | 1513 | 7.59 |
| 11:08 ET | 700 | 7.585 |
| 11:09 ET | 2966 | 7.555 |
| 11:11 ET | 18122 | 7.585 |
| 11:13 ET | 600 | 7.575 |
| 11:15 ET | 200 | 7.575 |
| 11:18 ET | 1426 | 7.575 |
| 11:20 ET | 25525 | 7.61 |
| 11:22 ET | 3742 | 7.56 |
| 11:26 ET | 2369 | 7.54 |
| 11:27 ET | 6145 | 7.5527 |
| 11:29 ET | 2800 | 7.5211 |
| 11:31 ET | 700 | 7.515 |
| 11:33 ET | 700 | 7.53 |
| 11:36 ET | 8259 | 7.54 |
| 11:38 ET | 700 | 7.497811 |
| 11:40 ET | 300 | 7.5 |
| 11:42 ET | 200 | 7.5 |
| 11:44 ET | 1200 | 7.5 |
| 11:45 ET | 100 | 7.5 |
| 11:47 ET | 1200 | 7.52 |
| 11:49 ET | 2595 | 7.56 |
| 11:51 ET | 4033 | 7.57 |
| 11:54 ET | 1400 | 7.56 |
| 11:56 ET | 6013 | 7.54 |
| 11:58 ET | 500 | 7.53 |
| 12:00 ET | 3300 | 7.53 |
| 12:02 ET | 3389 | 7.56 |
| 12:03 ET | 4535 | 7.58 |
| 12:05 ET | 2003 | 7.575 |
| 12:07 ET | 2165 | 7.565 |
| 12:09 ET | 1400 | 7.57 |
| 12:12 ET | 1100 | 7.57 |
| 12:14 ET | 530 | 7.57 |
| 12:16 ET | 1499 | 7.57 |
Sep 19, 2024
CorMedix Inc. Announces New Commercial Agreement, from 8:00AM ET on Thursday Sep 19, 2024 by Dow Jones
8:00AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 13, 2024
CorMedix Inc. to Present at the Cantor Global Healthcare Conference, from 8:30AM ET on Friday Sep 13, 2024 by Dow Jones
8:30AM ET on Friday Sep 13, 2024 by Dow Jones
Sep 9, 2024
CorMedix Inc. Announces New Commercial Agreement, from 10:52AM ET on Monday Sep 09, 2024 by Dow Jones
10:52AM ET on Monday Sep 09, 2024 by Dow Jones
Aug 26, 2024
DJ CorMedix Initiated at Buy by Rodman & Renshaw, from 7:14AM ET on Monday Aug 26, 2024 by Dow Jones
7:14AM ET on Monday Aug 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CorMedix Inc | 419.5M | -8.2x | --- |
Zevra Therapeutics Inc | 435.1M | -4.6x | --- |
Cipla Ltd | 15.8B | 0.0x | --- |
Elite Pharmaceuticals Inc | 404.4M | 20.4x | --- |
Calliditas Therapeutics AB | 1.2B | -22.6x | --- |
Incannex Healthcare Inc | 32.5M | 0.0x | --- |
Company Information
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Contact Information
- Headquarters
- 300 Connell Drive, Suite 4200BERKELEY HEIGHTS, NJ, United States 07922
- Phone
- 908-517-9500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Myron Kaplan
- Chief Executive Officer, Director
- Joseph Todisco
- Chief Financial Officer, Executive Vice President
- Matthew David
- Executive Vice President, Head of Clinical and Medical Affairs
- Elizabeth Massonhurlburt
- Executive Vice President, Chief Commercial Officer
- Erin Mistry
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $419.5M |
|---|---|
Revenue (TTM) | $806.1K |
Shares Outstanding | 55.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.60 |
EPS | $-0.93 |
Book Value | $1.28 |
P/E Ratio | -8.2x |
Price/Sales (TTM) | 520.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7,212.46% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
